Antares Pharma Inc (ATRS) Declines Again; Strong Momentum for Sellers

October 13, 2017 - By test

Investors sentiment decreased to 2.07 in Q2 2017. Its down 0.80, from 2.87 in 2017Q1. It dived, as 16 investors sold Antares Pharma Inc shares while 14 reduced holdings. 36 funds opened positions while 26 raised stakes. 53.64 million shares or 13.47% more from 47.27 million shares in 2017Q1 were reported.
Kingdon Capital Mgmt Limited Liability Corp stated it has 946,987 shares. Barclays Public Ltd holds 30,694 shares or 0% of its portfolio. Perkins Cap Management Incorporated accumulated 10,000 shares or 0.04% of the stock. Moreover, Gsa Cap Ptnrs Llp has 0.04% invested in Antares Pharma Inc (NASDAQ:ATRS). Tiaa Cref Invest Limited Liability Corp stated it has 0% in Antares Pharma Inc (NASDAQ:ATRS). Armistice Limited Liability Corp holds 2.34% in Antares Pharma Inc (NASDAQ:ATRS) or 5.70 million shares. Jacobs Levy Equity Mgmt holds 28,970 shares or 0% of its portfolio. Schwab Charles Invest Management Incorporated has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Deutsche Bank & Trust Ag reported 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS). Hightower Advsr Limited Liability Company holds 0% in Antares Pharma Inc (NASDAQ:ATRS) or 12,600 shares. 14,590 were reported by Prudential Inc. Alliancebernstein L P accumulated 0% or 36,900 shares. Benjamin F Edwards And has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Fuller Thaler Asset Management reported 0.03% stake. One Trading Lp invested 0% in Antares Pharma Inc (NASDAQ:ATRS).

Since June 9, 2017, it had 1 insider purchase, and 0 sales for $363,272 activity.

The stock of Antares Pharma Inc (NASDAQ:ATRS) is a huge mover today! About 16.04M shares traded or 671.15% up from the average. Antares Pharma Inc (NASDAQ:ATRS) has risen 207.14% since October 14, 2016 and is uptrending. It has outperformed by 190.44% the S&P500.
The move comes after 5 months negative chart setup for the $362.86M company. It was reported on Oct, 14 by Barchart.com. We have $2.14 PT which if reached, will make NASDAQ:ATRS worth $21.77 million less.

Wall Street await Antares Pharma Inc (NASDAQ:ATRS) to release earnings on November, 8. Analysts forecast earnings per share of $-0.03, up exactly $0.01 or 25.00 % from 2014’s $-0.04 EPS. After posting $-0.02 EPS for the previous quarter, Antares Pharma Inc’s analysts now forecast 50.00 % negative EPS growth.

Antares Pharma Inc (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 7 analyst reports since March 9, 2016 according to SRatingsIntel. The stock of Antares Pharma Inc (NASDAQ:ATRS) earned “Buy” rating by H.C. Wainwright on Friday, June 23. On Monday, August 7 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. The firm has “Buy” rating by Jefferies given on Tuesday, October 10. The company was maintained on Wednesday, March 9 by Jefferies. H.C. Wainwright initiated Antares Pharma Inc (NASDAQ:ATRS) on Friday, September 8 with “Buy” rating.

More important recent Antares Pharma Inc (NASDAQ:ATRS) news were published by: Fool.com which released: “Why Antares Pharma Inc Plummeted Today” on October 13, 2017, also Seekingalpha.com published article titled: “Antares Pharma (ATRS)”, Seekingalpha.com published: “Antares Pharma: Will October Deliver A Triple Play?” on October 09, 2017. More interesting news about Antares Pharma Inc (NASDAQ:ATRS) was released by: Marketwatch.com and their article: “Antares Pharma stock plunges more than 30% after FDA letter” with publication date: October 12, 2017.

Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has market cap of $362.86 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.